Summary
For Year 2026-27, Marksans Pharma reports the following shareholding: Total Promoters at 43.87%, Mutual Fund at 4.66%, Insurance at 0%, Foreign Institutional Investors at 16.76%, Domestic Institutional Investors at 1.91%, and Retail at 32.79%. This breakdown provides a quick snapshot of ownership distribution for Marksans Pharma in 2026-27.
Marksans Pharma FAQs
As of 04-2026, the promoter shareholding in Marksans Pharma stands at 43.87% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Marksans Pharma is 16.76% and 1.91% respectively.
The retail shareholding of the Marksans Pharma is 32.79%.
Changes in shareholding patterns of Marksans Pharma can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Marksans Pharma are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
